annual cash & cash equivalents:
$340.24M+$106.03M(+45.27%)Summary
- As of today (June 29, 2025), AKRO annual cash & cash equivalents is $340.24 million, with the most recent change of +$106.03 million (+45.27%) on December 31, 2024.
- During the last 3 years, AKRO annual cash & cash equivalents has risen by +$189.75 million (+126.10%).
- AKRO annual cash & cash equivalents is now at all-time high.
Performance
AKRO Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$185.92M-$154.32M(-45.36%)Summary
- As of today (June 29, 2025), AKRO quarterly cash & cash equivalents is $185.92 million, with the most recent change of -$154.32 million (-45.36%) on March 31, 2025.
- Over the past year, AKRO quarterly cash & cash equivalents has dropped by -$437.93 million (-70.20%).
- AKRO quarterly cash & cash equivalents is now -70.20% below its all-time high of $623.85 million, reached on March 31, 2024.
Performance
AKRO quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
AKRO Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +45.3% | -70.2% |
| 3 y3 years | +126.1% | +23.6% |
| 5 y5 years | +425.2% | +293.5% |
AKRO Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +126.1% | -70.2% | +23.6% |
| 5 y | 5-year | at high | +425.2% | -70.2% | +293.5% |
| alltime | all time | at high | >+9999.0% | -70.2% | +293.5% |
AKRO Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $185.92M(-45.4%) |
| Dec 2024 | $340.24M(+45.3%) | $340.24M(+7.6%) |
| Sep 2024 | - | $316.06M(+1.8%) |
| Jun 2024 | - | $310.36M(-50.3%) |
| Mar 2024 | - | $623.85M(+166.4%) |
| Dec 2023 | $234.21M(-6.2%) | $234.21M(-13.1%) |
| Sep 2023 | - | $269.55M(-39.3%) |
| Jun 2023 | - | $444.16M(+72.2%) |
| Mar 2023 | - | $257.88M(+3.2%) |
| Dec 2022 | $249.77M(+66.0%) | $249.77M(-33.2%) |
| Sep 2022 | - | $374.00M(+110.4%) |
| Jun 2022 | - | $177.73M(+18.1%) |
| Mar 2022 | - | $150.49M(+0.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2021 | $150.48M(-19.6%) | $150.48M(-8.8%) |
| Sep 2021 | - | $164.94M(+4.7%) |
| Jun 2021 | - | $157.54M(-16.2%) |
| Mar 2021 | - | $187.96M(+0.4%) |
| Dec 2020 | $187.24M(+189.0%) | $187.24M(-2.8%) |
| Sep 2020 | - | $192.68M(+204.6%) |
| Jun 2020 | - | $63.25M(+33.9%) |
| Mar 2020 | - | $47.24M(-27.1%) |
| Dec 2019 | $64.79M(-14.7%) | $64.79M(-56.2%) |
| Sep 2019 | - | $147.84M(-9.1%) |
| Jun 2019 | - | $162.65M(+133.0%) |
| Mar 2019 | - | $69.80M(-8.1%) |
| Dec 2018 | $75.97M(>+9900.0%) | $75.97M |
| Dec 2017 | $598.00K | - |
FAQ
- What is Akero Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Akero Therapeutics?
- What is Akero Therapeutics annual cash & cash equivalents year-on-year change?
- What is Akero Therapeutics quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Akero Therapeutics?
- What is Akero Therapeutics quarterly cash & cash equivalents year-on-year change?
What is Akero Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of AKRO is $340.24M
What is the all time high annual cash & cash equivalents for Akero Therapeutics?
Akero Therapeutics all-time high annual cash & cash equivalents is $340.24M
What is Akero Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, AKRO annual cash & cash equivalents has changed by +$106.03M (+45.27%)
What is Akero Therapeutics quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of AKRO is $185.92M
What is the all time high quarterly cash & cash equivalents for Akero Therapeutics?
Akero Therapeutics all-time high quarterly cash & cash equivalents is $623.85M
What is Akero Therapeutics quarterly cash & cash equivalents year-on-year change?
Over the past year, AKRO quarterly cash & cash equivalents has changed by -$437.93M (-70.20%)